VINORELBINE PIERRE FABRE vinorelbine 50mg/5mL (as tartrate) injection vial

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

vinorelbine tartrate, Quantity: 13.85 mg/mL (Equivalent: vinorelbine, Qty 10 mg/mL)

Pieejams no:

Pierre Fabre Australia Pty Ltd

Zāļu forma:

Injection, concentrated

Kompozīcija:

Excipient Ingredients: water for injections

Ievadīšanas:

Intravenous

Vienības iepakojumā:

1 x 5mL, 10 x 5mL

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

Vinorelbine Pierre Fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. Vinorelbine Pierre Fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage IB or greater.

Produktu pārskats:

Visual Identification: A clear, colourless to pale yellow solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Autorizācija statuss:

Licence status A

Autorizācija datums:

2000-08-04